Abstract
Introduction: The UK government introduced the two-week rule (TWR) to improve the diagnosis and treatment of gastrointestinal (GI) cancers. This updated review systematically identifies new articles since 2009 and presents an overview of the previous and new findings combined for both upper GI cancer (UGCs) and colorectal cancers (CRCs).
Methods: We analysed all peer-reviewed articles and conference abstracts with GI cancer detection rates following TWR referral and/or the proportion of TWR-referred GI cancers from the total number diagnosed during the study period. We reported average cancer detection rates and split the data according to four time periods to determine whether TWR effectiveness improved over time.
Results: The average cancer detection rate by the TWR for all studies was 11.6% for CRC and 8.3% for UGC. We found a decrease in cancer detection rates over time for CRC from 14.4% in 2000-2002 to 7.2% in 2009-2012. However, UGC detection rates increased over time from 8.5% in 2000-2002 to 11.4% in 2005-2008. We found that on average, 30.8% of CRCs and 28.8% of UGCs were detected following referrals using the TWR system and that these proportions had increased over time from 30.6% to 38.4% for CRC and from 26.8% to 52% for UGC.
Conclusion: The TWR is not still sufficiently effective in diagnosing GI cancers in patients, suggesting that the referral guidelines need to be improved. Our findings do suggest that the TWR is being used more frequently than alternative routes.
Keywords: Gastrointestinal cancer, two-week referral, fast-track, cancer detection rate.
Current Cancer Therapy Reviews
Title:Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review
Volume: 10 Issue: 1
Author(s): Kymberley Thorne, Hayley A. Hutchings and Glyn Elwyn
Affiliation:
Keywords: Gastrointestinal cancer, two-week referral, fast-track, cancer detection rate.
Abstract: Introduction: The UK government introduced the two-week rule (TWR) to improve the diagnosis and treatment of gastrointestinal (GI) cancers. This updated review systematically identifies new articles since 2009 and presents an overview of the previous and new findings combined for both upper GI cancer (UGCs) and colorectal cancers (CRCs).
Methods: We analysed all peer-reviewed articles and conference abstracts with GI cancer detection rates following TWR referral and/or the proportion of TWR-referred GI cancers from the total number diagnosed during the study period. We reported average cancer detection rates and split the data according to four time periods to determine whether TWR effectiveness improved over time.
Results: The average cancer detection rate by the TWR for all studies was 11.6% for CRC and 8.3% for UGC. We found a decrease in cancer detection rates over time for CRC from 14.4% in 2000-2002 to 7.2% in 2009-2012. However, UGC detection rates increased over time from 8.5% in 2000-2002 to 11.4% in 2005-2008. We found that on average, 30.8% of CRCs and 28.8% of UGCs were detected following referrals using the TWR system and that these proportions had increased over time from 30.6% to 38.4% for CRC and from 26.8% to 52% for UGC.
Conclusion: The TWR is not still sufficiently effective in diagnosing GI cancers in patients, suggesting that the referral guidelines need to be improved. Our findings do suggest that the TWR is being used more frequently than alternative routes.
Export Options
About this article
Cite this article as:
Thorne Kymberley, Hutchings A. Hayley and Elwyn Glyn, Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152459
DOI https://dx.doi.org/10.2174/157339471001140815152459 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes
Mini-Reviews in Medicinal Chemistry Anticancer Studies of Leucovorin against Methotrexate Induced Genotoxicity in Swiss Albino Mice
Letters in Drug Design & Discovery Drug Delivery Strategies for the Treatment of Helicobacter pylori Infections
Current Pharmaceutical Design Synthesis, In vitro α-Glucosidase Inhibitory Potential and Molecular Docking Studies of 2-Amino-1,3,4-Oxadiazole Derivatives
Medicinal Chemistry Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract
Current Pharmaceutical Design Extrinsic Factors Promoting Insulin Producing Cell-Differentiation and Insulin Expression Enhancement-Hope for Diabetics.
Current Stem Cell Research & Therapy Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design Stem Cell Guardians – Old and New Perspectives in LSC Biology
Current Drug Targets In silico Strategies to Probe Stereoselective Interactions of Multidrug Resistant Transporter P-glycoprotein
Letters in Drug Design & Discovery subject Index To Volume 2
Current Molecular Medicine Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors
Current Medicinal Chemistry Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions
Current Medicinal Chemistry